The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma
Featured:
Krina Patel
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
In the first-in-human trial of mezigdomide plus dexamethasone in patients with R/R MM by Hartley-Brown et al. (2024), which of the following was the most common adverse event?
A
B
C
D
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled: Sequencing immune-based therapies in B-cell malignancies. Here the Multiple Myeloma Hub is pleased to share the session: Next wave of immune-based therapies: What you need to know, which focused on relapsed/refractory (R/R) multiple myeloma (MM) and was presented by Krina Patel, MD Anderson Cancer Center, Houston, US.
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma
Listen to the podcast here:
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma
In this presentation, Patel discusses novel targets and therapies for multiple myeloma, such as cereblon E3 ligase modulators (CELMoDs), bispecific antibodies targeting FcRH5, trispecific antibodies, and G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapies. Patel also provides an overview of key ongoing trials of immunotherapy combinations for the treatment of MM (Table 1).
Table 1. Key ongoing clinical trials of combination therapies in R/R MM*
|
BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; GPRC5D, G protein-coupled receptor class C group 5 member D; MM, multiple myeloma; R/R, relapsed/refractory. *Adapted from Clinicaltrials.gov. |
||
|
NCT number |
Phase |
Aim |
|---|---|---|
|
NCT05850234† |
Ib/II |
To evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect, and immunogenicity of GC012F in subjects with R/R MM and determine the recommended phase II dose. |
|
NCT05509530‡ |
II |
To evaluate the safety and efficacy of anti-BCMA/GPRC5D CAR Tcell therapy in treating R/R MM. |
|
NCT06121843§ |
I |
To evaluate the safety, effectiveness, and tolerable dose of BMS986393 in novel combinations in participants with R/R MM. |
Watch or download the presentation to learn more about:
-
Clinical outcomes for novel immunomodulatory drugs in R/R MM
-
Key ongoing pivotal trials for CAR T-cell therapy, including:
-
Phase II QUINTESSENTIAL trial of CA0881000, a GPRC5D-directed CAR T-cell therapy in R/R MM
-
Phase III CARTITUDE-5 trial of bortezomib, lenalidomide, and dexamethasone followed by ciltacabtagene autoleucel in newly diagnosed MM for whom allogeneic stem cell transplant is not planned as initial therapy
-
Phase III KarMMa-9 trial of idecabtagene vicleucel with lenalidomide maintenance therapy versus lenalidomide maintenance therapy alone in adult participants with newly diagnosed MM who have suboptimal response after autologous stem cell transplantation
-
Phase I/II OriCAR-017-US-PI open-label, single-arm, multicenter trial of OriCAR-017 in MM
-
Key novel data for MM treatments presented at EHA 2024
Key points
-
Following B-cell maturation antigen (BCMA) therapy, new targets for bispecifics and CAR T cells may facilitate better outcomes; however, additional information is required to determine optimal sequencing and/or combinations.
-
It is imperative to optimize supportive care and preventive measures for infections, deep vein thrombosis, gastrointestinal disorders, and other toxicities.
-
Biomarkers have the potential to significantly improve clinical decision-making; more research is needed to determine the mechanisms of resistance for these novel immunotherapies.
Q&A
This symposium closed with a panel Q&A session with live audience participation, where our panelists shared their perspectives on the next wave of immune-based therapies in R/R MM.
Q&A | Next wave of immune-based therapies in relapsed/refractory multiple myeloma
This independent educational activity was supported by Bristol Myers Squibb. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
References
